Periosteal Osteosarcoma A Single-Institution Experience
Periosteal Osteosarcoma A Single-Institution Experience
复制标题
DOI：
10.1002/cncr.25718
复制
发表时间：
2011-04-15
期刊：
影响因子：
6.2
通讯作者：
Ferrari, Stefano
中科院分区：
文献类型：
--
作者：
Cesari, Marilena;Alberghini, Marco;Ferrari, Stefano
背景：骨膜骨肉瘤是骨肉瘤的一种罕见变异型。广泛的手术切除是主要的治疗方法，但关于化疗的作用仍存在争议。本研究的目的是回顾和分析影响在单一机构接受治疗的骨膜骨肉瘤患者生存的临床和治疗相关因素。方法：33例骨膜骨肉瘤患者（男19例，女14例），中位年龄16岁（年龄范围6-32岁），接受手术（32例）和放射治疗（1例）。 14例3级肿瘤患者根据不同方案接受高级别骨肉瘤化疗。结果：10年总生存率为84%。唯一一位没有接受手术的患者在9个月后因病去世；其余 32 名患者的 10 年无病生存率为 65%。生存率不受接受化疗的影响。接受化疗的患者10年总生存率为86%，仅接受局部治疗的患者10年总生存率为83% (P = .73)。结论：作者的经验表明，骨膜骨肉瘤的治疗只需要广泛手术切除肿瘤，辅助化疗并不能提高生存率。癌症 2011；117：1731-5。 (C) 2010 年美国癌症协会。
BACKGROUND: Periosteal osteosarcoma is a rare variant of osteosarcoma. Wide surgical removal is the mainstay of treatment, but controversy remains about the role of chemotherapy. The objective of this study was to review and analyze the clinical and treatment-related factors that influence the survival of patients with periosteal osteosarcoma who received treatment in a single institution. METHODS: Thirty-three patients with periosteal osteosarcoma (19 males and 14 females) with a median age of 16 years (range, ages 6-32 years) underwent surgery (32 patients) and received radiotherapy (1 patient). Chemotherapy was received according to different regimens for high-grade osteosarcoma by 14 patients who had grade 3 tumors. RESULTS: The 10-year overall survival rate was 84%. The only patient who did not undergo surgery died of disease after 9 months; for the remaining 32 patients the 10-year disease-free survival rate was 65%. Survival was not influenced by the receipt of chemotherapy. The patients who received chemotherapy had a 10-year overall survival rate of 86%, and those who received only local treatment had an overall survival rate of 83% (P = .73). CONCLUSIONS: The authors' experience indicated that the treatment of periosteal osteosarcoma requires only wide surgical removal of the tumor and that adjuvant chemotherapy does not improve survival. Cancer 2011;117:1731-5. (C) 2010 American Cancer Society.